Al-Batran S-E et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone in resectable esophagogastic adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. ASCO 2022;Abstract 4003.
Ambrosini M et al. ALK inhibitors in patients with ALK fusion-positive GI cancers: An international data set and a molecular case series. JCO Precis Oncol 2022;6(1):e2200015. Abstract
Anderson E et al. A comparison of clinicopathologic outcomes across neoadjuvant and adjuvant treatment modalities in resectable gastric cancer. JAMA Netw Open 2021;4(12):e2138432. Abstract
Andre T et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study. ASCO 2022;Abstract 244.
Bendell JC et al. CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). Gastrointestinal Cancers Symposium 2021;Abstract TPS449.
Catenacci DVT et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2B+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). ASCO 2021;Abstract 4010.
Catenacci DV et al. Toward a treatment sequencing strategy: A systemic review of treatment regimens in advanced gastric cancer/gastroesophageal junction adenocarcinoma. Oncologist 2021;26(10):e1704-29. Abstract
Chao J et al. A phase 2 trial combining pembrolizumab and palliative radiation therapy in gastroesophageal cancer in augment abscopal immune responses. Adv Radiat Oncol 2021;7(1):100807. Abstract
Cercek A et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363-76. Abstract
Cercek A et al. Single agent PD-1 blockade as curative-intent therapy in mismatch repair deficient locally advanced rectal cancer. ASCO 2022;Abstract LBA5.
Chau I et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648. Gastrointestinal Cancers Symposium 2022;Abstract 4035.
Chuang J et al. Therapeutic advances and challenges in the management of HER2-positive gastroesophageal cancers. Diseases 2022;10(2):23. Abstract
Doki Y et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022;386(5):449-62. Abstract
Fontana E, Smyth EC. Dissecting response and resistance to anti-PD-1 therapy in microsatellite-unstable gastric cancer. Cancer Discov 2021;11(9):2126-8. Abstract
Friedman CF et al. Atezolizumab treatment of tumors with high tumor mutational burden from MyPathway, a multicenter, open-label, phase IIa multiple basket study. Cancer Discov 2022;12(3):654-69. Abstract
Fucà G et al. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer 2022;10(2):e004001. Abstract
Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9. Abstract
Huynh J et al. Immunotherapy in gastroesophageal cancers: Current evidence and ongoing trials. Curr Treat Options Oncol 2021;22(11):100. Abstract
Janjigian YY et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40. Abstract
Janjigian YY et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727-30. Abstract
Kasi PM et al. Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI). Gastrointestinal Cancers Symposium 2022;Abstract 56.
Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. New Engl J Med 2021;384(13):1191-203. Abstract
Kelly RJ et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. ASCO 2021;Abstract 4003.
Klempner SJ et al. ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA). ASCO 2021;Abstract 4045.
Kwon M et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov 2021;11(9):2168-85. Abstract
Lorenzen S et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Results from the phase II RAMIRIS study of the German Gastric Cancer Study Group at AIO. Eur J Cancer 2022;165:48-57. Abstract
Lou H et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 2021;326(10):916-25. Abstract
Mansoor W et al. Early weight loss as a prognostic factor in patients with advanced gastric cancer: Analyses from REGARD, RAINBOW, and RAINFALL phase III studies. Oncologist 2021;26(9):e1538-47. Abstract
Maron SB, Klempner SJ. Are you a TMBeliever? Mutations and atezolizumab response in solid tumors. Cancer Discov 2022;12(3):602-3. Abstract
Metges JP et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. Gastrointestinal Cancers Symposium 2022;Abstract 241.
Sahin U et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 2021;32(5):609-19. Abstract
Shitara K et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603(7903):942-8. Abstract
Shitara K et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19(11):1437-48. Abstract
Shen L et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study. ESMO 2021;Abstract LBA52.
Siddiqui AZ, Almhanna K. Beyond chemotherapy, PD-1, and HER-2: Novel targets for gastric and esophageal cancer. Cancers 2021;13(17):4322. Abstract
Sun J-M et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet 2021;398(10302):759-71. Abstract
Van Cutsem E et al. Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. ESMO 2021;Abstract LBA55.
Verschoor YL et al. Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: Final clinical analysis of the NICHE study. ASCO 2022;Abstract 3511.
Wang Z-X et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell 2022;40(3):277-88.e3. Abstract
Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224-35. Abstract
Xu J et al. Sintilimab plus chemotherapy (chemo) versus chemo as the first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. ESMO 2021;Abstract LBA53.
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). ASCO 2022;Abstract 4048.
Zhang L et al. ERBB2 copy number as a quantitative biomarker for real-world outcomes to anti-human epidermal growth factor receptor 2 therapy in advanced gastroesophageal adenocarcinoma. JCO Precis Oncol 2022;6:e2100330. Abstract